Targeting MET amplification in EGFR-mutant non-small-cell lung cancer

Publication date: Available online 29 May 2020Source: The Lancet Respiratory MedicineAuthor(s): Rafael Rosell, Imane Chaib, Mariacarmela Santarpia
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research

Related Links:

Authors: Matsui A, Morise M, Tanaka I, Ozone S, Matsuzawa R, Koyama J, Hase T, Hashimoto N, Sato M, Hasegawa Y Abstract In advanced non-small cell lung cancer (NSCLC), the reported incidence of febrile neutropenia (FN) caused by docetaxel (DTX) is 10-20% in clinical trial data. However, FN incidence caused by DTX in real-world setting remains unclear. We evaluated FN incidence caused by DTX and identify risk factors of FN in real-world setting. 171 NSCLC patients treated with DTX were retrospectively analyzed and 44 (26%) developed FN. Multivariate analysis identified higher age (≥65 years) and prior history of ...
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
Authors: Rocco D, Gregorc V, Della Gravara L, Lazzari C, Palazzolo G, Gridelli C Abstract INTRODUCTION: The development of immune checkpoint inhibitors (ICI) has represented a revolution in the treatment of non-small cell lung cancer (NSCLC) and has established a new standard of care for different settings. However, through adaptive changes, cancer cells can develop resistance mechanisms to these drugs, hence the necessity for novel immunotherapeutic agents. AREAS COVERED: This paper explores the immunotherapeutics currently under investigation in phase I clinical trials for the treatment of NSCLC as monotherap...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
Therapy targeting programmed death-1 or programmed death-1 ligand-1 (PD-1/PD-L1) has been developed for various solid malignant tumors, such as melanoma and non-small-cell lung cancer (NSCLC), but this approac...
Source: BMC Gastroenterology - Category: Gastroenterology Authors: Tags: Case report Source Type: research
Radiation therapy (RT) is part of definitive treatment for patients with unresectable non-small cell lung cancer (NSCLC). Despite major technological advances in imaging and conformal delivery techniques, the tolerances of adjacent normal tissues continue to limit target volume doses [1,2]. In patients receiving RT for thoracic malignancies, the most frequent toxicities occur in the lungs and/or heart. Radiation-induced cardiac toxicity (RICT) may present as multiple pathologies including myocardial fibrosis, ischemic heart disease, valvular abnormalities and pericarditis [3].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Conditions:   Metastatic Non-small Cell Lung Cancer (NSCLC);   Non-squamous NSCLC Interventions:   Drug: ABP 215;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin Sponsors:   Amgen;   Parexel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: LINC00460 is overexpressed in NSCLC tissues and can promote the growth of NSCLC cells by targeting miR-539. PMID: 32633366 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Publication date: Available online 9 July 2020Source: The Annals of Thoracic SurgeryAuthor(s): Shane P. Smith, Adam J. Bograd, Gal Levy, Shu-Ching Chang, Alex S. Farivar, Ralph W. Aye, Brian E. Louie, Eric Vallières
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor ...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
CONCLUSIONS: Coverage of ctDNA-based panel testing for cancer indications increased from 2015 to 2019. The trend in private payer and Medicare coverage is an increasing number of coverage policies, number of positive policies, and scope of coverage. We found that Medicare coverage policies are evolving to pan-cancer uses, signifying a significant shift in coverage frameworks. Given that genomic medicine is rapidly changing, payers and policymakers (eg, guideline developers) will need to continue to evolve policies to keep pace with emerging science and standards in clinical care. PMID: 32634780 [PubMed - as supplied by publisher]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
czyk Aptamers are short, single-stranded oligonucleotides which are capable of specifically binding to single molecules and cellular structures. Aptamers are also known as “chemical antibodies”. Compared to monoclonal antibodies, they are characterized by higher reaction specificity, lower molecular weight, lower production costs, and lower variability in the production stage. Aptamer research has been extended during the past twenty years, but only Macugen® has been accepted by the Food and Drug Administration (FDA) to date, and few aptamers have been examined in clinical trials. In vitro s...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Respiratory Medicine